Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027.
12 Health Care Stocks Moving In Thursday's Intraday Session Gainers PepGen (
NASDAQ: PEPG ) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Trading SMID Biotech Stocks In A Volatile Market Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024 ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding.
Earnings Scheduled For March 26, 2024 Companies Reporting Before The Bell • bluebird bio (
NASDAQ:BLUE ) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
